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Objective:Although technological improvements continue to advance the designs of aortic stent grafts, miniaturization of
the required delivery systems would allow their application to be available to a wider range of patients and potentially
decrease the access difficulties that are encountered. We performed this feasibility study to determine if thin-film NiTi
(Nitinol) could be used as a covering for stent grafts ranging from 16 mm to 40 mm in diameter. Specifically, we wished
to determine the profile reduction attainable and improve the flexibility of our design.
Methods:Using a novel hot-sputter deposition technique, we created sheets of thin-filmNiTi (TFN)with a tensile strength
of >500 Megapascal (MPa) and thickness of 5-10 microns. TFN was used to cover stents, which were then deployed in
vitro. Patterned thin film was fabricated via a lift-off technique; grafts were constructed with stents ranging from 16-40
mm and deployed in a pulsatile flow system from the smallest diameter polymer tubing into which the stent and TFN
would fit. The bending/stiffness ratio vs similar sized expanded polytetrafluoroethylene (ePTFE)-covered stents was also
determined.
Results: TFN was created in both non-patterned and patterned forms, with a tensile strength of>100MPa for the latter.
We created devices that were successfully deployed via delivery systems half the size of fabric-covered stent grafts (ie, the
16 mm stent graft that originally was delivered via a 16French (F) system was reduced to 8F, and the 40 mm stent graft
delivered via a 24F system was reduced to 12F). No migration of the devices was observed with deployment in both
straight and curved tubing, which was sized so that the stent grafts were oversized by 20%. Both forms of the thin-film
were noted to be more flexible than the same sized ePTFE stent graft, and the patterned graft had an additional 15-30%
flexibility vs the non-patterned film.
Conclusion: These in vitro results demonstrate the feasibility of TFN for covering stent grafts designed for placement in
the aorta. The delivery profile can be significantly reduced across a wide range of sizes, while the material remained more
flexible than ePTFE. (J Vasc Surg 2009;50:375-80.)
Clinical Relevance: This article describes a basic science/engineering project with clear implications for clinical applica-
tion of an aortic endograft. Our continuing projects along these lines will be reported as these data become available. The
clinical relevance is also addressed within the body of the manuscript, particularly in the discussion.Since the introduction of covered stents, there has been
rapid application of these devices for a variety of clinical
situations. Parodi’s description of abdominal aortic aneu-
rysm (AAA) repair using a stent graft was followed by the
diffusion of a variety of commercially available products
into the vascular surgeons’ armamentarium, and these stent
grafts are now used routinely for the treatment of both
AAAs and thoracic aneurysms.1,2 One of the factors that
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doi:10.1016/j.jvs.2009.03.028currently limits the utilization of these grafts, particularly
with thoracic endovascular aneurysm repair (TEVAR), is
their large caliber and long delivery systems, which can be
up to 25 French (F) (8.3 mm) for a 46 mm thoracic
endograft. Insertion of large delivery catheters can make
the arterial access and tracking through small, tortuous, or
calcified vessels difficult or impossible.
There have been considerable attempts to miniaturize
the pre-deployment diameter of aortic stent grafts and their
delivery components. Currently available aortic stent grafts
are constructed using a combination of a metallic stent,
usually stainless steel, or an alloy such as nitinol (NiTi) with
a covering made of either a woven polyester fabric (such as
the Cook Zenith grafts, Cook Inc, Indianapolis, Ind) or
expanded polytetrafluoroethylene (ePTFE) as with W.L.
Gore & Associates (Flagstaff, Ariz) TAG and Excluder
devices. The major determinant of the diameter of these
devices is the covering (ie, 50% of catheter space is occupied
by the ePTFE covering), and not the stent itself. Thus,
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for reducing the diameter of the entire delivery system.
Our laboratory has been exploring the feasibility of
using thin-film NiTi (TFN) as a novel covering for aortic
stent grafts, to reduce the delivery system diameter. Utiliz-
ing a novel hot target sputter deposition process, we have
created corrosive-resistant TFN with a thickness as small as
1 micron to a thickness as large as 15 microns and from it
fashioned a variety of devices.3,4 The biocorrosive and
fatigue properties of thin-film NiTi have been cursorily
evaluated in previous studies. These data showed the TFN
to be more corrosion resistant than either bulk NiTi or
316L stainless steel and the TFN did not undergo any
degradation during a one million cycle pulsatile flow test
under 115 mmHg systolic blood pressure.5 Based on these
data from our laboratory, we do not expect fatigue degra-
dation of the TFN material (ie, load and strain levels in
covered stent smaller than heart valve) or significant corro-
sion of the TFN (ie, less corrosive than existing stents on
the market).
TFN has many advantageous qualities including: (1) a
long and safe history of human implantation in the form of
numerous types of devices in multiple anatomic locations;
(2) superelastic qualities which allow it to undergo a stress-
induced phase transformation (elastically recoverable strain
of 10%); (3) shape memory properties which provide easy
deformation in the martensite phase at a low temperature
and shape recovery in the austenite phase at elevated tem-
perature (eg, body temperature); and (4) a tensile strength
of greater than 500 Megapascal (MPa).6 These properties
suggest TFN has potential as a covering for the larger sized
stent grafts required to treat aneurysms of the aorta while
dramatically reducing the required thickness of the stent
covering. In addition to material properties advantages,
TFN-covered stents are expected to be comparable in terms
of cost to ePTFE devices, where the majority of the cost is
associated with attachment issues (ie, hand sewing) rather
than the material costs of NiTi. This current feasibility
study set out to address the following related questions: (1)
can we construct TFN stent grafts of larger sizes (16-40
mm) and successfully deploy them in vitro; (2) canwe provide
these stent grafts with the necessary pre-deployment flexi-
bility required to navigate tortuous vessels during the de-
livery process and to conform to the aorta following de-
ployment; and (3) can we reduce the diameter of the stent
graft deployment system?
METHODS
Thin-film NiTi creation. Films were deposited on a
4” silicon wafer buffered with a 500 nm silicon oxide layer
to both retard silicide formation and prevent the film from
adhering to the substrate. The bulk NiTi source was bom-
barded with argon while the substrate was translated in 80
mm sections perpendicular to the sputtering direction. This
technique has led to the production of TFN with compo-
sitional variation of less than 1 atomic percent.7 The film
was then removed from the substrate and crystallized for
120 minutes at 500°C in a vacuum of less than 1  107torr. The film was then micro-machined using lithographic
techniques into rectangular sheets and rolled onto 0.64
mm steel cylinders in preparation for insertion into the
appropriate delivery catheter. The TFN material used for
this study had an austenite finish temperature of approxi-
mately 34°C as measured from differential scanning calo-
rimeter (DSC) following deposition and removal from the
wafer. The superelastic and shape recovery properties of
this film were measured with a mechanical load frame at
body temperature and room temperature, respectively.
Stent graft fabrication and in vitro deployment.
The TFN-covered stent and delivery system consists of
three major components, the stent, TFN, and the cath-
eter. The stent was obtained from a commercially available
ePTFE-covered thoracic stent. The ePTFE was subse-
quently removed from the thoracic stent. The TFN sheets
were sized to provide full coverage of the deployed thoracic
stent. A polymer catheter was used for delivery, andwe used
the smallest diameter tubing into which both the bare stent
and the TFN would fit without deforming either structure.
The TFN material was mechanically constrained and in-
serted in the delivery catheter. Following this, the thoracic
stent was mechanically constrained and inserted into the
delivery catheter. In this process, the TFN is not mechani-
cally attached to the thoracic stent, but in future models
this will be revised. Also, in this scenario, the TFN is on the
vessel side of the stent. Placing the film on the lumen side
would require mechanical fixation which should be rela-
tively easy to achieve. Once in the delivery catheter, the
mechanical constraint was removed (ie, the film partially
deployed in the catheter). The diameters of the actual
delivered devices ranged from 16-40 mm. To determine
the minimum size deployment catheter the stent graft
could be inserted into, successively smaller sizes were tested
for each stent, and the tubing with the smallest diameter
into which the bare stent would fit was used for the subse-
quent stent graft delivery.
These stent graft constructs were deployed from the
polymer catheter with a push-wire system into polyvinyl
chloride (PVC) tubing (ie, simulating the vascular curva-
ture) with a range of diameters (12-44 mm). Flow was
provided in the PVC tubing via a Harvard Apparatus
pulsatile pump (Harvard Medical, Hollison, Mass) with a
systole/diastole ratio of 40:60 and a stroke volume of
10-30 cc per stroke (600-2400 cc/minute) to evaluate
for in vitro migration of our stent grafts under pulsatile
conditions.
Micromachined patterns through thin-film NiTi.
In addition to evaluating thin-film NiTi-covered stents, we
also investigated the use of patterned NiTi film. Patterned
NiTi film contains small diameter holes increasing the
flexibility of the material and is analogous to a woven fabric.
We hypothesized that the patterned film would dramati-
cally reduce the bending stiffness of the stent/delivery
system when compared to non-patterned film and also
allow for better conformability to the target blood vessel.
Using a lift-off method and photolithography, holes as
small as 20 microns and as large as 70 microns were
hotor
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ducing patterned TFN is to create 50 micron deep trenches
using photolithography and a deep reactive ion etching
(DRIE) technique (Fig 1). Following this, a 500 nm cop-
Fig 1. The lift-off process used to fabricate patterns on
text for details. DRIE, Deep reactive ion etching; PR, p
Fig 2. Bare metal stent and thin-film nitinol (NiTi) before assem-
bly (A). This 37-mm stent graft is also shown collapsed inside a
12F delivery catheter (B).














16 mm 16F 7F 8F
20 mm 18F 8F 9F
26 mm 20F 10F 10F
37 mm 24F 11F 12F
40 mm 24F 11F 12F
NiTi, Nitinol; F, French.per (Cu) sacrificial layer and a 500 nm silicon dioxide(SiO2) barrier layer are deposited by e-beam evaporation
and plasma-enhanced chemical vapor deposition (PECVD)
techniques, respectively. The TFN is deposited by direct
current sputtering process onto the SiO2. Cu and SiO2
layers are removed and stand-alone film is crystallized at
500°C for 120 minutes in a vacuum of less than 1  107
torr.
RESULTS
Preliminary work with the commercial stent grafts was
performed, and we determined that stents were easily col-
lapsed and re-inserted into delivery tubing half the diameter
of the original system less one French size. The addition of
TFN-covering onto the stents allowed the stent graft com-
binations to be fitted into delivery catheters half the original
diameter; that is, the thin-film covering led to one addi-
film nitinol (NiTi) is displayed above schematically. See
esist; Cu, copper; SiO2, silicon dioxide.
Fig 3. Displayed in longitudinal view is a 37-mm thin-film nitinol
(NiTi)-covered stent graft uniformly deployed in a 30mmpulsatile
flow circuit following placement via a 12F delivery catheter.thintional French size (Table) (Fig 2). One stent was used for
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how delivery catheter size changes as a function of graft
material (ie, from ePTFE to TFN). There was no observed
structural damage to either the stents or the TFN at these
diameters, and the stents were then successfully deployed in
our pulsatile circuit in tubing for which the stent grafts were
oversized by 20% (Fig 3). Migration of the stent graft
combination was not observed at any pulsatile conditions
measured up to a flow rate of 47 cc/second (pressure of
500mmHg). Furthermore, these in vitro deployment tests
used the same sheaths for femoral access and there was no
significant kinking or lack of pushability with no added
reinforcement necessary for the delivery system.
The TFN contained holes that were diamond-shaped
with dimensions of 20 10microns, 40 20microns, and
60  30 microns. Fig 4 shows a scanning electron micro-
scope (SEM) image of the 5-micron-thick patterned TFN.
As can be seen from the photograph, the patterning is
uniform. The in vitro tests of insertion of TFN-covered
stents in the delivery catheter and deployment were per-
formed 20 times per TFN-covered stent. No damage or
failure was observed as the force needed to push the device
out of the delivery catheter was quite small compared to the
high tensile strength (greater than 100 MPa) of TFN. For
this particular film, the holes were diamond-shaped and
approximately 20 microns along the longest axis and 10
microns along the shortest axis. Note that the NiTi edges
are clean and smooth and do not contain undercutting as is
observed in most wet etching techniques. The SEM also
clearly shows that the hole registrations are uniform and
equally spaced throughout the film. These features allow
the patterned TFN sheets to be deformed without adverse
effects on subsequent stent graft deployment. The stent
grafts with the patterned coverings were then deployed in
curved tubing with a radius of curvature of 0.2 m under
Fig 4. Scanning electron micrograph image of patterned thin-
film nitinol (NiTi) demonstrating uniform, diamond-patterned
holes.pulsatile conditions. Again, no migration was observed.Stent grafts were then removed from the in vitro system.
Analysis of the thin film demonstrated no structural
damage.
Calculations were performed to determine the bending
stiffness of the patterned thin film vs the non-patterned
product. This was used as a surrogate for determining the
flexibility of the material. Fig 5 displays the bending stiff-
ness ratio for the two materials over a range of increasing
thickness for the film in the pre-deployment configuration
for a 12F delivery system. The scale is set so that a ratio of
1 is equal to that for an ePTFE-covered stent graft of the
same dimensions. Both forms of the TFN have increased
flexibility relative to the ePTFE stent graft, and there was a
15-30% increase in flexibility across the scale for the pat-
terned thin film vs the non-patterned form. In general,
lower bending stiffness is desirable to increase the trackabil-
ity of the delivery system. Therefore, the film should be as
thin as possible. Using the strength properties of TFN (500
MPa) and the strength properties for ePTFE (1 MPa),
the thickness of TFN could be 1/500th the value of ePTFE
(ie, 0.5 m) and be effectively as strong as ePTFE. This
suggests all the thicknesses considered in Fig 5 are substan-
tially stronger than current ePTFE stent structures.
DISCUSSION
These results demonstrate in vitro the feasibility of
using TFN for the construction of aortic stent grafts with
the benefit of reducing the diameter of the delivery systems
for these devices. The systems for a variety of commercially
available stent grafts were reduced by what is clearly a
clinically relevant degree (half of the original delivery sys-
tem). To be fair, we do not have a finished prototype of this
novel covered stent and anticipate that fastening the stent
to the thin film and adding a bifurcated stent graft may add
to the profile. However, the dramatic reduction of the
Fig 5. A plot of the bending stiffness ratio of TFN vs ePTFE
where a ratio of 0.5 indicates that TFN is half the bending stiffness
of expanded polytetrafluoroethylene (ePTFE) (ie, more compli-
ant). In this case, patterned thin-film nitinol (TFN) (red line) is
compared to non-patterned TFN (black line). NiTi, Nitinol; Fr,
French.space occupied by the thin-film NiTi covering is clear, with
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more, the many design and engineering facets needed for a
bifurcated AAA graft are not issues with regards to TEVAR,
where access issues due to the size of the graft and delivery
system limit their use. This raises the possibility that devel-
opment of lower profile stents could lead to even smaller
systems than described in this document. That is, with
previous coverings there was little impetus to miniaturize
the stent, as the bulk of the diameter derived from the
covering itself. We have also demonstrated that our lift-off
method represents an acceptable fabrication process to
produce TFN with sufficient flexibility of both the pre-
deployment construct and the deployed stent graft, at least
in an in vitro setting for stent grafts 16 mm in diameter.
NiTi is currently used routinely for many implantable
devices, and there have been few issues with biocompatibil-
ity. There are some concerns regarding the release of nickel,
although the clinical significance of these findings is not
known.5 There is a body of literature regarding the re-
sponse of endothelial cells and vascular smooth muscle cells
to NiTi surfaces. Both cell types appear to attach to the thin
films and undergo cell division in vitro.8 There are a variety
of modifications of the thin-film surface (for example,
surface roughness) that also impacts on the characteristics
of vascular cells when exposed to these surfaces. However,
it should be pointed out that the surface roughness of
thin-film NiTi (ie, 5 nm) is an order of magnitude smaller
than surface roughness of commercially available NiTi
stents (ie, 500 nm). With regards to thrombogenicity, the
data are unclear. Comparisons to stainless steel in vitro have
led to conflicting results,9,10 although in vivo work from
our laboratory suggests favorable characteristics.11 In addi-
tion to the chemical properties of the thin-film NiTi, the
impact of the mechanical configuration of the patterned
thin film on the biological response to the material also
needs to be evaluated, as it may be different than that of the
continuous thin-filmNiTi sheets. This is an area of ongoing
investigation in our laboratory.
In this study, endotension, permeability, and ultrafil-
tration characteristics through the patterned holes was not
evaluated. Given that platelets and red blood cells are on
the order of 5-10 m, the hole sizes used in this study may
allow leakage. However, standard lithography is capable of
2 m size features and e-beam lithography is capable of 0.1
m features. These small sizes would prevent leakage and
will be evaluated in future experiments. However, the
tensile strength of the thin-film NiTi itself is known to be
orders of magnitude stronger than ePTFE.
In addition to reducing the profile of larger stent grafts,
there are several other potential benefits of using thin-film
NiTi. One is a possible advantage with regards to infection
resistance. Although NiTi can become infected, this risk, at
least in other anatomic locations, is much less than that with
woven polyesters or ePTFE.12 We are currently evaluating
the ability of the material to withstand infection in vitro.
With regards to our particular sputter deposition tech-
nique, the main advantages are found in the uniformity of
our thin film and the ability to provide thicker deposits (upto 15 m), which is not possible with other techniques for
thin film production such as pulsed laser deposition.13 The
details of the deposition technique become particularly
critical when fabricating sheets of thin film for creating
larger stent grafts. Our technique is also faster with the
concomitant implications for industrial production of these
devices. Even at the extremely thin profiles afforded by our
thin-film NiTi fabrication, it should be remembered that
the tensile strength of NiTi is still several orders of magni-
tude greater than that afforded by ePTFE or woven poly-
esters. For example, the tensile strength of ePTFE is
roughly 10 MPa, and this number is significantly less when
it is in a tubular vs a sheet form. Thus, we can achieve a
thickness of our film for medical applications that can be
orders of magnitude thinner.
From a clinical standpoint, thoracic aortic aneurysms
appear to be the lesions most likely to benefit from these
devices for a number of reasons. Most significant among
these are the large diameter grafts required at this location.
Indeed, two grafts measuring 46 mm are soon to be avail-
able in the United States, and these have delivery systems of
24 and 25F diameter.14 Our current data suggest we could
deploy such a device via a 12 or 13F system. In addition to
the size itself, there is the issue of navigating these stent
grafts the long distance from the femoral or iliac conduit
access site where the smaller diameter device would clearly
be less difficult to successfully deliver to the thoracic aorta.
Another application to arise from an early design from this
study is that for a contralateral limb for AAA treatment. For
patients with limited iliac access unilaterally, the 16 mm
device we created could be delivered via an 8F sheath, while
a different 12 mm limb we created can be delivered via a 6F
sheath.
The above data support the feasibility of our design for
a TFN-covered stent graft in vitro for use in large arteries
(treatable by grafts 16 mm and larger). Although the data
are all in vitro, several questions regarding fabrication and
deployment have been successfully addressed. We are cur-
rently investigating the in vivo deployment of our stent
grafts in animal models.
A number of issues remain areas of active research,
including the fastening of the stent to the TFN, and fash-
ioning devices of more complex design, such as the bifur-
cated design required for an AAA stent graft. Also, as
mentioned above, endotension, permeability, and ultrafil-
tration characteristics were not tested using the patterned
TFN and will need to be evaluated in future studies as these
are crucial determinants in developing a successful stent
graft. Although the grafts in this study were constructed
with the thin film outside of the stent, we have also exper-
imented with designs where the thin film is inside the
supportive stent. In addition, there are designs with sup-
port wires of NiTi on the outside of the thin film to provide
external support to the film if it is not in apposition to an
arterial wall, ie, the portion of a large aneurysm between the
attachment zones. Finally, it should be pointed out that the
thin film itself need not be rolled to form cylinders; it can be
preformed and attached to itself or the stent by a variety of
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The patterned film in particular can be collapsed easily in
the martensite phase with recovery of the desired shape at
austenite phase (body temperature). We are also investigat-
ing tissue in-growth with our patterned grafts to determine
the appropriate size for adequate incorporation of these
stent grafts.
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